Frontiers in Pharmacology (Nov 2020)
Analysis of the Costs Associated With the Elective Evaluation of Patients Labelled as Allergic to Beta-Lactams or Nonsteroidal Antiinflamatory Agents
- Miriam Sobrino-García,
- Esther M. Moreno,
- Esther M. Moreno,
- Esther M. Moreno,
- Esther M. Moreno,
- Francisco J. Muñoz-Bellido,
- Francisco J. Muñoz-Bellido,
- Francisco J. Muñoz-Bellido,
- Maria T. Gracia-Bara,
- Maria T. Gracia-Bara,
- Elena Laffond,
- Elena Laffond,
- Elena Laffond,
- Inmaculada Doña,
- Inmaculada Doña,
- Inmaculada Doña,
- Cristina Martín,
- Cristina Martín,
- Eva M. Macías,
- Eva M. Macías,
- Eva M. Macías,
- Sonia de Arriba,
- Sonia de Arriba,
- Sonia de Arriba,
- Valle Campanón,
- Alicia Gallardo,
- Ignacio Dávila,
- Ignacio Dávila,
- Ignacio Dávila,
- Ignacio Dávila
Affiliations
- Miriam Sobrino-García
- Allergy Service, University Hospital of Salamanca, Salamanca, Spain
- Esther M. Moreno
- Allergy Service, University Hospital of Salamanca, Salamanca, Spain
- Esther M. Moreno
- Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain
- Esther M. Moreno
- Department of Biomedical and Diagnostic Sciences, Faculty of Medicine, University of Salamanca, Salamanca, Spain
- Esther M. Moreno
- Asthma, Allergic and Adverse Reactions (ARADyAL), Network for Cooperative Research in Health of Instituto de Salud Carlos III, Salamanca University Hospital, Salamanca, Spain
- Francisco J. Muñoz-Bellido
- Allergy Service, University Hospital of Salamanca, Salamanca, Spain
- Francisco J. Muñoz-Bellido
- Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain
- Francisco J. Muñoz-Bellido
- Department of Biomedical and Diagnostic Sciences, Faculty of Medicine, University of Salamanca, Salamanca, Spain
- Maria T. Gracia-Bara
- Allergy Service, University Hospital of Salamanca, Salamanca, Spain
- Maria T. Gracia-Bara
- Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain
- Elena Laffond
- Allergy Service, University Hospital of Salamanca, Salamanca, Spain
- Elena Laffond
- Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain
- Elena Laffond
- Department of Biomedical and Diagnostic Sciences, Faculty of Medicine, University of Salamanca, Salamanca, Spain
- Inmaculada Doña
- Asthma, Allergic and Adverse Reactions (ARADyAL), Network for Cooperative Research in Health of Instituto de Salud Carlos III, Salamanca University Hospital, Salamanca, Spain
- Inmaculada Doña
- Allergy Service, University Hospital of Malaga, Malaga, Spain
- Inmaculada Doña
- Biomedical Research Institute of Malaga (IBIMA), Malaga, Spain
- Cristina Martín
- Allergy Service, University Hospital of Salamanca, Salamanca, Spain
- Cristina Martín
- Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain
- Eva M. Macías
- Allergy Service, University Hospital of Salamanca, Salamanca, Spain
- Eva M. Macías
- Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain
- Eva M. Macías
- Department of Biomedical and Diagnostic Sciences, Faculty of Medicine, University of Salamanca, Salamanca, Spain
- Sonia de Arriba
- Allergy Service, University Hospital of Salamanca, Salamanca, Spain
- Sonia de Arriba
- Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain
- Sonia de Arriba
- Department of Biomedical and Diagnostic Sciences, Faculty of Medicine, University of Salamanca, Salamanca, Spain
- Valle Campanón
- Allergy Service, University Hospital of Salamanca, Salamanca, Spain
- Alicia Gallardo
- Allergy Service, University Hospital of Salamanca, Salamanca, Spain
- Ignacio Dávila
- Allergy Service, University Hospital of Salamanca, Salamanca, Spain
- Ignacio Dávila
- Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain
- Ignacio Dávila
- Department of Biomedical and Diagnostic Sciences, Faculty of Medicine, University of Salamanca, Salamanca, Spain
- Ignacio Dávila
- Asthma, Allergic and Adverse Reactions (ARADyAL), Network for Cooperative Research in Health of Instituto de Salud Carlos III, Salamanca University Hospital, Salamanca, Spain
- DOI
- https://doi.org/10.3389/fphar.2020.584633
- Journal volume & issue
-
Vol. 11
Abstract
Introduction: Being labelled as allergic to different drugs results in patients receiving other treatments, which are more toxic, less effective and more expensive. We aimed to analyze different studies of the costs of drug hypersensitivity assessment.Methods: A bibliographic search on studies regarding this issue was performed, including the available scientific evidence up to June 2020. We searched three databases with terms related to costs and allergy testing in drug hypersensitivity reactions.Results: Our search revealed 1,430 publications, of which 20 met the inclusion criteria. In the manuscript, prospective studies evaluating the costs of the evaluation of patients with suspected allergy to beta-lactams or non-steroidal anti-inflammatory drugs are analyzed. Also, comment is made on the costs associated with incorrect labeling as non-steroidal anti-inflammatory drug or penicillin hypersensitivity.Conclusions: Taking all costs into account, the study of drug hypersensitivity is not expensive, particularly considering the economic and clinical consequences of labeling a patient with hypersensitivity to drugs.
Keywords
